Psychedelic-assisted therapy: What psychiatrists need to know

In early February, the Therapeutic Goods Administration announced that from 1 July 2023, authorised psychiatrists will be able to prescribe medicines containing psychedelic substances, psilocybin and MDMA, for the treatment of PTSD and treatment-resistant depression.

This webinar had RANZCP President, A/Prof Vinay Lakra, and Prof Richard Harvey, Chair of the Psychedelic Assisted Therapy Steering Group, who outlined the College’s position, role, and explore the implications for psychiatry and the mental health sector.

The event was hosted by Sharon McGowan, RANZCP CEO and members had the opportunity to participate in a live Q&A during the webinar and submit their questions prior in the registration form below. 

Disclaimer

This session is a Member benefit of the RANZCP and for educational purposes only. The information may represent views of the author and not necessarily the views of the College. Information is subject to change and the College does not warrant that the information is current at the time of viewing and accepts no liability for any loss or damage suffered by you or a patient directly or indirectly as a result of relying on information provided and should not be a substitute for individual clinical judgement. By accessing e-learning sessions you also agree to the RANZCP Website Terms of Use Agreement.